Skip to main content
PMC home page
Cellular & Molecular Biology Letters logoLink to Cellular & Molecular Biology Letters
. 2008 Apr 10;13(2):155–181. doi: 10.2478/s11658-007-0046-6

Natriuretic peptides in cardiovascular diseases

Mariusz Piechota 1, Maciej Banach 2,✉, Anna Jacoń 3, Jacek Rysz 4
PMCID: PMC6275881  PMID: 17965966

Abstract

The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin. The activities of natriuretic peptides and endothelins are strictly associated with each other. ANP and BNP inhibit endothelin-1 (ET-1) production. ET-1 stimulates natriuretic peptide synthesis. All natriuretic peptides are synthesized from polypeptide precursors. Changes in natriuretic peptides and endothelin release were observed in many cardiovascular diseases: e.g. chronic heart failure, left ventricular dysfunction and coronary artery disease.

Key words: Atrial natriuretic peptide, Brain natriuretic peptide, C-type natriuretic peptide, Dendroaspis natriuretic peptide, Urodilatin, Endothelin-1

Full Text

The Full Text of this article is available as a PDF (592.6 KB).

Abbreviations used

ACTH

adrenocorticotropic hormone

ANP

atrial natriuretic peptide

AVP

arginine vasopressin

BNP

brain natriuretic peptide

CHF

chronic heart failure

CNP

C-type natriuretic peptide

cGMP

cyclic guanosine monophosphate

DNP

dendroaspis natriuretic peptide

ET

endothelin

FGF

fibroblast growth factor

NO

nitric oxide

NYHA

New York Heart Association

PAI

plasminogen activator inhibitor

PGDF

platelet derived growth factor

TGF

transforming growth factor

TIMP

tissue inhibitor of matrix metalloproteinase

TNF

tumor necrosis factor

References

  • 1.de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg A. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci. 1981;28:89–94. doi: 10.1016/0024-3205(81)90370-2. [DOI] [PubMed] [Google Scholar]
  • 2.Kangawa K., Matsuo H. Purification and complete amino acid sequence of alfa-human atrial natriuretic polypeptide (alfa-hANP) Biochem. Biophys. Res. Commun. 1984;118:131–139. doi: 10.1016/0006-291x(84)91077-5. [DOI] [PubMed] [Google Scholar]
  • 3.Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78–81. doi: 10.1038/332078a0. [DOI] [PubMed] [Google Scholar]
  • 4.Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M., Ogawa H., Okumura K., Mukoyama M., Nakao K. Localisation and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203. doi: 10.1161/01.cir.90.1.195. [DOI] [PubMed] [Google Scholar]
  • 5.Barr C.S., Rhodes P., Struthers A.D. C-type natriuretic peptide. Peptides. 1996;17:1243–1251. doi: 10.1016/s0196-9781(96)00110-6. [DOI] [PubMed] [Google Scholar]
  • 6.de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;361:316–322. doi: 10.1016/S0140-6736(03)13976-1. [DOI] [PubMed] [Google Scholar]
  • 7.Komatsu Y., Nakao K., Suga S., Ogawa Y., Mukoyama M., Arai H., Shirakami G., Hosoda K., Nakagawa O., Hama N. C-type natriuretic peptide in rats and humans. Endocrinology. 1991;129:1104–1106. doi: 10.1210/endo-129-2-1104. [DOI] [PubMed] [Google Scholar]
  • 8.Stein B.C., Levin R.I. Natriuretic peptides: Physiology, therapeutic potential and risk stratification in ischemic heart disease. Am. Heart J. 1998;135:914–923. doi: 10.1016/s0002-8703(98)70054-7. [DOI] [PubMed] [Google Scholar]
  • 9.Schweitz H., Vigne P., Minier D. A new member of the natriuretic peptide family is present in the venom of green mamba (dendroaspis angusticeps) J. Biol. Chem. 1992;267:13928–13932. [PubMed] [Google Scholar]
  • 10.Schirger J.A., Heublein D.M., Chen H.H., Lisy O., Jougasaki M., Wennberg P.W., Burnett J.C., Jr. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and ist increase during human heartbfailure. Mayo Clin. Proc. 1999;74:126–130. doi: 10.4065/74.2.126. [DOI] [PubMed] [Google Scholar]
  • 11.Hickey K.A., Rubanyi G., Paul R.J., Higsmith R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am. J. Physiol. 1985;248:C550–C556. doi: 10.1152/ajpcell.1985.248.5.C550. [DOI] [PubMed] [Google Scholar]
  • 12.Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]
  • 13.Ogawa K., Oida A., Sugimura H., Kaneko N., Nogi N., Hasumi M., Numao T., Nagao I., Mori S. Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients-comparison of electrocardiography, chest radiography and echocardiography. Circ. J. 2002;66:122–126. doi: 10.1253/circj.66.122. [DOI] [PubMed] [Google Scholar]
  • 14.Cheung B., Kumana C. Natriuretic peptides-relevance in cardiac disease. JAMA. 1998;280:1983–1984. doi: 10.1001/jama.280.23.1983. [DOI] [PubMed] [Google Scholar]
  • 15.Koskinas K., Tzellos T.G., Gougoulias K., Gougoulias G., Papakonstantinou C., Kouvelas D. Simvastatin-induced rhabdomyolysis: a case study on clinical-decision making based on the evidence-based medicine approach. Arch. Med. Sci. 2007;3:267–271. [Google Scholar]
  • 16.Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N. Engl. J. Med. 1998;339:321–328. doi: 10.1056/NEJM199807303390507. [DOI] [PubMed] [Google Scholar]
  • 17.Kalra P.R., Clague J.R., Bolger A.P. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation. 2003;107:571–573. doi: 10.1161/01.cir.0000047280.15244.eb. [DOI] [PubMed] [Google Scholar]
  • 18.Grabowski M., Malek L.A., Karpinski G., Filipiak K.J., Opolski G. BNP in the differential diagnosis of amiodarone-induced pulmonary toxicity: a case report and review of the literature. Arch. Med. Sci. 2006;2:131–133. [Google Scholar]
  • 19.Banach M., Markuszewski L., Zasłonka J., Grzegorczyk J., Okoński P., Jegier B. The role of inflammation in the pathogenesis of atherosclerosis. Przegl. Epidemiol. 2004;58:663–670. [PubMed] [Google Scholar]
  • 20.Piechota M., Banach M., Irzmański R., Piechota-Urbańska M., Kowalski J., Pawlicki L. NT-proBNP levels correlate with organ failure in septic patients — preliminary report. Postepy Hig. Med. Dosw. (Online) 2006;60:632–636. [PubMed] [Google Scholar]
  • 21.Brown A.M., Sease K.L., Robey J.L., Shofer F.S., Hollander J.E. The impact of B-type natriuretic peptide in addition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome. Ann. Emerg. Med. 2007;49:153–163. doi: 10.1016/j.annemergmed.2006.08.024. [DOI] [PubMed] [Google Scholar]
  • 22.Irzmański R., Banach M., Piechota M., Barylski M., Serwa-Stępień E., Cierniewski C., Jegier B., Kowalski J., Pawlicki L. BNP concentration in patients with mitral stenosis. Dependence on selected morphological parameters. Arch. Med. Sci. 2006;2:159–163. [Google Scholar]
  • 23.Brunner-La Rocca H.P., Kiowski W., Ramsay D., Sütsch G. Therapeutic benefits of increasing natriuretic peptides levels. Cardiovasc. Res. 2001;51:510–520. doi: 10.1016/s0008-6363(01)00302-9. [DOI] [PubMed] [Google Scholar]
  • 24.Gutkowska J., Antunes-Rodrigues J., McCann S.M. Atrial natriuretic peptide in brain and pituitary gland. Physiol. Rev. 1997;77:465–515. doi: 10.1152/physrev.1997.77.2.465. [DOI] [PubMed] [Google Scholar]
  • 25.Pidgeon G.B., Richards A.M., Nichols M.G. Differing metabolism and bioactivity of atrial and brain natriuretic peptide in essential hypertension. Hypertension. 1996;27:906–913. doi: 10.1161/01.hyp.27.4.906. [DOI] [PubMed] [Google Scholar]
  • 26.Irzmański R., Banach M., Piechota M., Kowalski J., Barylski M., Cierniewski C., Pawlicki L. Atrial, Brain Natriuretic Peptide and Endothelin-1 concentration in patients with idiopathic arterial hypertension. The dependence on the selected morphological parameters. Clin. Exp. Hypertens. 2007;29:149–164. doi: 10.1080/10641960701361593. [DOI] [PubMed] [Google Scholar]
  • 27.de Lemos J.A., Morrow D.A. Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation acute coronary syndromes. Am. Heart J. 2007;153:450–453. doi: 10.1016/j.ahj.2007.02.012. [DOI] [PubMed] [Google Scholar]
  • 28.Kowalski, J., Banach, M., Barylski, M., Irzmanski, R. and Pawlicki, L. Carvedilol modifies antioxidant status of patients with stable angina. Cell. Mol. Biol. Lett.13 (2008) in press. [DOI] [PMC free article] [PubMed]
  • 29.Kapoun A.M., Liang F., O’Young G., Damm D.L., Quon D., White R.T., Munson K., Lam A., Schreiner G.F., Protter A.A. B-type natriuretic peptide exerts broad functional opposition to transforming growth factorbeta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. 2004;94:453–461. doi: 10.1161/01.RES.0000117070.86556.9F. [DOI] [PubMed] [Google Scholar]
  • 30.Dietz J.R. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc. Res. 2005;68:8–17. doi: 10.1016/j.cardiores.2005.06.008. [DOI] [PubMed] [Google Scholar]
  • 31.McDowell G., Patterson C., Maguire S., Shaw C., Nicholls D.P., Hall C. Variability of Nt-proANP and C-ANP. Eur. J. Clin. Invest. 2002;32:545–548. doi: 10.1046/j.1365-2362.2002.01031.x. [DOI] [PubMed] [Google Scholar]
  • 32.Witthaut R., Busch C., Fraunberger P., Walli A., Seidel D., Pilz G., Stuttmann R., Speichermann N., Verner L., Werdan K. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intens. Care Med. 2003;29:1696–1702. doi: 10.1007/s00134-003-1910-0. [DOI] [PubMed] [Google Scholar]
  • 33.Maisel A.S., Clopton P., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H., Steg G., Westheim A., Knudsen C.W., Perez A., Kazanegra R., Bhalla V., Herrmann H.C., Aumont M.C., McCullough P.A. BNP Multinational Study Investigators. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am. Heart J. 2004;147:1078–1084. doi: 10.1016/j.ahj.2004.01.013. [DOI] [PubMed] [Google Scholar]
  • 34.Clerico A., Lervasi G., Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm. Metab. Res. 1999;31:487–498. doi: 10.1055/s-2007-978782. [DOI] [PubMed] [Google Scholar]
  • 35.Cosin Aguilar J., Hernandiz Martinez A., Diez Gil J.L., Capdevila Carbonell C., Salvador Sanz A., Diago Torrent J.L., Rivera Otero M., Paya Serrano R., Bertomeu Martinez V., Sogorb Garri F., Jordan Torrent A., Mainar Latorre L., Grau Jornet G., Marti Llinares S., Miro Palau V. Grupo de Estudio de la Disfuncion Ventricular Izquierda en la Comunidad. Value of NTproBNP concentration in an out-of-hospital adult population. Rev. Esp. Cardiol. 2003;56:236–244. doi: 10.1016/s0300-8932(03)76859-6. [DOI] [PubMed] [Google Scholar]
  • 36.Bozkurt B., Mann D.L. Use of Biomarkers in the Management of Heart Failure. Are We There Yet? Circulation. 2003;107:1231–233. doi: 10.1161/01.cir.0000057608.97285.20. [DOI] [PubMed] [Google Scholar]
  • 37.Irzmanski R., Barylski M., Banach M., Piechota M., Kowalski J., Cierniewski C., Pawlicki L. The concentration of atrial and brain natriuretic peptide in patients with idiopathic arterial hypertension. Med. Sci. Monit. 2007;13:CR449–456. [PubMed] [Google Scholar]
  • 38.Rubanyi G.M., Polokoff M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 1994;46:325–415. [PubMed] [Google Scholar]
  • 39.Goto K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol. Pharm. Bull. 2001;24:1219–1230. doi: 10.1248/bpb.24.1219. [DOI] [PubMed] [Google Scholar]
  • 40.Benigni A., Remuzzi G. Endothelin antagonists. Lancet. 1999;353:133–138. doi: 10.1016/S0140-6736(98)09423-9. [DOI] [PubMed] [Google Scholar]
  • 41.Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA. 1989;86:2863–2867. doi: 10.1073/pnas.86.8.2863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ducancel F. Endothelin-like peptides. Cell Mol. Life Sci. 2005;62:2828–2839. doi: 10.1007/s00018-005-5286-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kedzierski R.M., Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 2001;41:851–876. doi: 10.1146/annurev.pharmtox.41.1.851. [DOI] [PubMed] [Google Scholar]
  • 44.Pawlowska Z., Jerczynska H., Szemraj J., Baranska P., Swiatkowska M., Cierniewski C.S. Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell Mol. Biol. Lett. 2002;7:1153–1157. [PubMed] [Google Scholar]
  • 45.Ohmnishi M., Wada A., Tsutamoto T., Sawaki M., Fujii M., Matsumoto T., Kinoshita M. Significant role of endothelin-A and endothelin-B receptor sin renal function in congestive heart failure. J. Cardiovasc. Pharmacol. 2000;36(5):44–49. doi: 10.1097/00005344-200036051-00044. [DOI] [PubMed] [Google Scholar]
  • 46.Wang J., Chiou W.J., Gagne G.D., Wu-Wong J.R. Internalization of type-A endothelin receptor. J. Cardiovasc. Pharmacol. 2000;36(5):61–65. doi: 10.1097/00005344-200036051-00021. [DOI] [PubMed] [Google Scholar]
  • 47.Iglarz M., Schiffrin E.L. Role of endothelin-1 in hypertension. Curr. Hypertens. Rep. 2003;5:144–148. doi: 10.1007/s11906-003-0071-4. [DOI] [PubMed] [Google Scholar]
  • 48.Haynes W.G., Ferro C.J., O’Kane K.P., Somerville D., Lomax C.C., Webb D.J. Systemic endothelin receptor blocade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93:1860–1870. doi: 10.1161/01.cir.93.10.1860. [DOI] [PubMed] [Google Scholar]
  • 49.Irzmański R., Serwa-Stępień E., Barylski M., Banach M., Kowalski J., Pawlicki L. Endothelial dysfunction in hypertension. The role of natriuretic peptides and endothelin. Kardiol. Pol. 2005;63(2):457–461. [PubMed] [Google Scholar]
  • 50.Schiffrin E.L., Intengan H.D., Thibault G., Touyz R.M. Clinical significance of endothelin in cardiovascular disease. Curr. Opin. Cardiol. 1997;12:354–367. [PubMed] [Google Scholar]
  • 51.Burrell K.M., Molenaar P., Dawson P.J., Kauman A.J. Contractile and arrythmic effect of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J. Pharmacol. Exp. Ther. 2000;292:449–459. [PubMed] [Google Scholar]
  • 52.Saetrum Opgaard O., Möller S., de Vries R., Edvinsson L., Saxena P.R. Positive inotropic responses mediated by endothelin ET (A) and ET (B) receptors in human myocardial trabecule. Clin. Sci. (Lond.) 2000;99:161–168. doi: 10.1042/cs19990302. [DOI] [PubMed] [Google Scholar]
  • 53.Fabris B., Chen B., Pupic V., Perich R., Johnston C.I. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. J. Cardiovasc. Pharmacol. 1990;15(2):56–59. doi: 10.1097/00005344-199000152-00003. [DOI] [PubMed] [Google Scholar]
  • 54.Weber K.T. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin. Nephrol. 1997;17:461–464. [PubMed] [Google Scholar]
  • 55.Benigni A., Perico G., Remuzzi G. Endothelin antagonists and renal protection. J. Cardiovasc. Pharmacol. 2000;35(4):75–79. doi: 10.1097/00005344-200000002-00017. [DOI] [PubMed] [Google Scholar]
  • 56.Bassenge E. Endothelial function in different organs. Prog. Cardiovasc. Dis. 1996;39:209–228. doi: 10.1016/s0033-0620(96)80002-8. [DOI] [PubMed] [Google Scholar]
  • 57.Dries D.L. Relevance of molecular forms of brain natriuretic peptide for natriuretic peptide research. Hypertension. 2007;49:971–973. doi: 10.1161/HYPERTENSIONAHA.107.087254. [DOI] [PubMed] [Google Scholar]
  • 58.Hama N., Itoh H., Shirakami G., Nakagawa O., Suga S., Ogawa Y., Masuda I., Nakanishi K., Yoshimasa T., Hashimoto Y. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995;92:1558–1564. doi: 10.1161/01.cir.92.6.1558. [DOI] [PubMed] [Google Scholar]
  • 59.Peacock W.F. The B-type natriuretic peptide assay: A rapid test for heart failure. Cleve. Clin. J. Med. 2002;69:243–251. doi: 10.3949/ccjm.69.3.243. [DOI] [PubMed] [Google Scholar]
  • 60.Qi W., Mathisen P., Kjekshus J., Simonsen S., Bjornerheim R., Endresen K., Hall C. Natriuretic peptides in patients aortic stenosis. Am. Heart J. 2001;142:725–732. doi: 10.1067/mhj.2001.117131. [DOI] [PubMed] [Google Scholar]
  • 61.Nagaya N., Nishikimi T., Uematsu M., Satoh T., Kyotani S., Sakamaki F., Kakishita M., Fukushima K., Okano Y., Nakanishi N., Miyatake K., Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865–870. doi: 10.1161/01.cir.102.8.865. [DOI] [PubMed] [Google Scholar]
  • 62.Fagan K.A., McMurtry I.F., Rodman D.M. Role of endothelin-1 in lung disease. Respir. Res. 2001;2:90–101. doi: 10.1186/rr44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Teder P., Noble P.W. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am. J. Respir. Cell Mol. Biol. 2000;23:19–26. doi: 10.1165/ajrcmb.23.1.f192. [DOI] [PubMed] [Google Scholar]
  • 64.Thomson A.B., Keelan M., Thiesen A. Small bowel review: normal physiology part 2. Dig. Dis. Sci. 2001;46:2588–2607. doi: 10.1023/a:1012746622735. [DOI] [PubMed] [Google Scholar]
  • 65.Zuccarello M. Endothelin: the “prime suspect” in cerebral vasospasm. Acta Neurochir. Suppl. 2001;77:61–65. [PubMed] [Google Scholar]
  • 66.Saito Y., Nakao K., Nishimura K., Sugawara A., Okumura K., Obata K., Sonoda R., Ban T., Yasue H., Amura H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation. 1987;76:115–124. doi: 10.1161/01.cir.76.1.115. [DOI] [PubMed] [Google Scholar]
  • 67.Bonow R.O. New insights into the cardiac natriuretic peptides. Circulation. 1996;93:1946–1950. doi: 10.1161/01.cir.93.11.1946. [DOI] [PubMed] [Google Scholar]
  • 68.Tsutamoto T., Wada A., Maeda K., Hisanaga T., Mabuchi N., Hayashi M., Ohnishi M., Sawaki M., Fujii M., Horie H., Sugimoto Y., Kinoshita M. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur. Heart J. 1999;20:1799–1807. doi: 10.1053/euhj.1999.1746. [DOI] [PubMed] [Google Scholar]
  • 69.Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H., Clopton P., Steg P.G., Westheim A., Knudsen C.W., Perez A., Kazanegra R., Herrmann H.C., McCullough P.A., Breathing Not Properly Multinational Study Investigators Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 2002;347:161–167. doi: 10.1056/NEJMoa020233. [DOI] [PubMed] [Google Scholar]
  • 70.Cosin Aguilar J., Rodriguez Padial L., Zamorano Gomez J.L., Aristegui Urrestarazu R., Armada Pelaez B., Hernandiz Martinez A., Aguilar Llopis A., Masramon Morell X. Coronary risk differences in hypertensive patients of different autonomous communities. CORONARY study. Rev. Clin. Esp. 2004;204:614–625. doi: 10.1016/s0014-2565(04)71564-7. [DOI] [PubMed] [Google Scholar]
  • 71.McDonagh T.A., Robb S.D., Murdoch D.R., Morton J.J., Ford I., Morrison C.E., Tunstall-Pedoe H., McMurray J.J., Dargie H.J. Biochemical detection of left ventricular systolic dysfunction. Lancet. 1998;351:9–13. doi: 10.1016/s0140-6736(97)03034-1. [DOI] [PubMed] [Google Scholar]
  • 72.Dao Q., Krishnaswamy P., Kazanegra R., Harrison A., Amirnovin R., Lenert L., Clopton P., Alberto J., Hlavin P., Maisel A.S. Utility of Btype natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting. J. Am. Coll. Cardiol. 2001;37:379–385. doi: 10.1016/s0735-1097(00)01156-6. [DOI] [PubMed] [Google Scholar]
  • 73.Cocco G., Chu D. Weight reduction decreases NT-proBNP levels in obsese coronary patients with chronic diastolic heart failure. Arch. Med. Sci. 2007;3:112–116. [Google Scholar]
  • 74.Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson S.G., Poole-Wilson P.A., Sutton G.C. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349–1352. doi: 10.1016/S0140-6736(97)06031-5. [DOI] [PubMed] [Google Scholar]
  • 75.Berger R., Huelsman M., Strecker K., Bojic A., Moser P., Stanek B., Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392–2397. doi: 10.1161/01.cir.0000016642.15031.34. [DOI] [PubMed] [Google Scholar]
  • 76.Tsutamoto T., Wada A., Maeda K., Hisanaga T., Maeda Y., Fukai D., Ohnishi M., Sugimoto Y., Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–516. doi: 10.1161/01.cir.96.2.509. [DOI] [PubMed] [Google Scholar]
  • 77.Collins S.P., Ronan-Bentle S., Storrow A.B. Diagnostic and prognostic usefulness of natriuretic peptides in Emergency Department patients with dyspnea. Ann. Emerg. Med. 2003;41:532–545. doi: 10.1067/mem.2003.113. [DOI] [PubMed] [Google Scholar]
  • 78.Maisel A.S., Koon J., Krishnaswamy P., Kazenegra R., Clopton P., Gardetto N., Morrisey R., Garcia A., Chiu A., De Maria A. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am. Heart J. 2001;141:367–374. doi: 10.1067/mhj.2001.113215. [DOI] [PubMed] [Google Scholar]
  • 79.Kimura K., Yamaguchi Y., Horii M., Kawata H., Yamamoto H., Uemura S., Saito Y. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur. J. Clin. Pharmacol. 2007;63:699–702. doi: 10.1007/s00228-007-0309-1. [DOI] [PubMed] [Google Scholar]
  • 80.Cheng V., Kazanagra R., Garcia A., Lenert L., Krishnaswamy P., Gardetto N., Clopton P., Maisel A. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J. Am. Coll. Cardiol. 2001;37:386–391. doi: 10.1016/s0735-1097(00)01157-8. [DOI] [PubMed] [Google Scholar]
  • 81.Kawakami R., Saito Y., Kishimoto I., Harada M., Kuwahara K., Takahashi N., Nakagawa Y., Nakanishi M., Tanimoto K., Usami S., Yasuno S., Kinoshita H., Chusho H., Tamura N., Ogawa Y., Nakao K. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation. 2004;110:3306–3312. doi: 10.1161/01.CIR.0000147829.78357.C5. [DOI] [PubMed] [Google Scholar]
  • 82.Greig D., Castro P., Ferrada M., Lim J., Lopez C., Braun S., Cordova S., Salazar M. Brain natriuretic peptide in primary pulmonary hypertension. Rev. Med. Chil. 2006;134:299–304. doi: 10.4067/s0034-98872006000300005. [DOI] [PubMed] [Google Scholar]
  • 83.Piechota M., Banach M., Irzmanski R., Barylski M., Piechota-Urbanska M., Kowalski J., Pawlicki sL. Plasma endothelin-1 levels in septic patients. J. Intensive Care Med. 2007;22:232–239. doi: 10.1177/0885066607301444. [DOI] [PubMed] [Google Scholar]
  • 84.Maeda K., Tsutamoto T., Wada A., Hisanaga T., Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am. Heart J. 1998;135:823–832. doi: 10.1016/s0002-8703(98)70041-9. [DOI] [PubMed] [Google Scholar]
  • 85.Emdin M., Passino C., Prontera C., Iervasi A., Ripoli A., Masini S., Zucchelli G.C., Clerico A. Cardiac natriuretic hormones, neuro hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin. Chem. Lab. Med. 2004;42:627–636. doi: 10.1515/CCLM.2004.108. [DOI] [PubMed] [Google Scholar]
  • 86.McKinsey T.A., Nolson E.N. Cardiac hypertrophy: sorting out the circuitry. Curr. Opin. Genet. Dev. 1999;9:267–274. doi: 10.1016/s0959-437x(99)80040-9. [DOI] [PubMed] [Google Scholar]
  • 87.Piechota M., Banach M., Irzmański R., Misztal M., Rysz J., Barylski M., Piechota-Urbańska M., Kowalski J., Pawlicki L. N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients. Cell. Mol. Biol. Lett. 2007;12:162–175. doi: 10.2478/s11658-006-0062-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Gardner R.S., Ozalp F., Murday A.J., Robb S.D., McDonagh T.A. N-terminal brain natriuretic peptide: the new gold standard in predicting mortality in patients with advanced heart failure. Eur. Heart J. 2003;24:1735–1743. doi: 10.1016/j.ehj.2003.07.005. [DOI] [PubMed] [Google Scholar]
  • 89.Hodges M., Bailey J.J., Church T.R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2003;107:e13. doi: 10.1161/01.cir.0000046777.74753.f8. [DOI] [PubMed] [Google Scholar]
  • 90.Hammerer-Lercher A., Ludwig W., Falkensammer G., Muller S., Neubauer E., Puschendorf B., Pachinger O., Mair J. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem. 2004;50:1174–1183. doi: 10.1373/clinchem.2003.028316. [DOI] [PubMed] [Google Scholar]
  • 91.Clerico A., Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin. Chem. 2004;50:33–50. doi: 10.1373/clinchem.2003.024760. [DOI] [PubMed] [Google Scholar]
  • 92.Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 2001;22:1527–1560. doi: 10.1053/euhj.2001.2783. [DOI] [PubMed] [Google Scholar]
  • 93.Jourdain P., Funck F., Bellorini M. Brain natriuretic peptide and heart failure, from bench to bedside. Ann. Cardiol. Angeiol. (Paris) 2004;53:193–199. doi: 10.1016/j.ancard.2004.02.015. [DOI] [PubMed] [Google Scholar]
  • 94.Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., Glazer R.D., Tognoni G., Cohn J.N., Val-HeFT Investigators Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in Val-HeFT. Circulation. 2003;107:1278–1283. doi: 10.1161/01.cir.0000054164.99881.00. [DOI] [PubMed] [Google Scholar]
  • 95.Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130. doi: 10.1016/s0140-6736(00)02060-2. [DOI] [PubMed] [Google Scholar]
  • 96.Brunner-La Roca H.P., Kaye D.M., Woods R.L., Hastings J., Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared to control subjects. J. Am. Coll. Cardiol. 2001;37:1221–1227. doi: 10.1016/s0735-1097(01)01172-x. [DOI] [PubMed] [Google Scholar]
  • 97.Abraham W.T., Lowes B.D., Ferguson D.A., Odom J., Kim J.K., Robertson A.D., Bristow M.R., Schrier R.W. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with advanced hemodynamically decompensated heart failure. J. Card. Fail. 1998;4:37–44. doi: 10.1016/s1071-9164(98)90506-1. [DOI] [PubMed] [Google Scholar]
  • 98.Tepper D. Frontiers in congestive heart failure: Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. Congest. Heart Fail. 2001;7:330. [PubMed] [Google Scholar]
  • 99.Banach M., Goch A., Misztal M., Rysz J., Barylski M., Jaszewski R., Goch J.H. Low output syndrome following aortic valve replacement. Predictors and prognosis. Arch. Med. Sci. 2007;3:117–122. [Google Scholar]
  • 100.Banach M., Drożdż J., Okoński P., Rysz J. Immunological aspects of the statins’ function in patients with heart failure. A raport from the Annual Conference of ESC — Heart Failure 2005. Cell. Mol. Immunol. 2005;2:433–437. [PubMed] [Google Scholar]
  • 101.Irzmański R., Piechota M., Barylski M., Banach M., Kowalski J., Serwa-Stępień E., Drożdż J., Pawlicki L. NT-proBNP in patients after acute coronary syndrome with ST segment elevation subjected to early posthospitalization cardiologic rehabilitation. Arch. Med. Sci. 2006;2:262–267. [Google Scholar]
  • 102.Sabatine M.S., Morrow D.A., de Lemos J.A., Omland T., Desai M.Y., Tanasijevic M., Hall C., McCabe C.H., Braunwald E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J. Am. Coll. Cardiol. 2004;44:1988–1995. doi: 10.1016/j.jacc.2004.07.057. [DOI] [PubMed] [Google Scholar]
  • 103.James S.K., Lindahl B., Siegbahn A., Stridsberg M., Venge P., Armstrong P., Barnathan E.S., Califf R., Topol E.J., Simoons M.L., Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275–281. doi: 10.1161/01.CIR.0000079170.10579.DC. [DOI] [PubMed] [Google Scholar]
  • 104.de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., Hall C., Cannon C.P., Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 2001;345:1014–1021. doi: 10.1056/NEJMoa011053. [DOI] [PubMed] [Google Scholar]
  • 105.Bassan R., Potsch A., Maisel A., Tura B., Villacorta H., Nogueira M.V., Campos A., Gamarski R., Masetto A.C., Moutinho M.A. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur. Heart J. 2005;26:234–240. doi: 10.1093/eurheartj/ehi033. [DOI] [PubMed] [Google Scholar]
  • 106.Jarai R., Iordanova N., Jarai R., Raffetseder A., Woloszczuk W., Gyöngyösi M., Geyer G., Wojta J., Huber K. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal proatrial natriuretic peptide. Eur. Heart J. 2005;26:250–256. doi: 10.1093/eurheartj/ehi038. [DOI] [PubMed] [Google Scholar]
  • 107.Skrzypiec, M. and Spring, A. Plasma levels of atrial (ANP) and brain (BNP) natriuretic peptides in patients with unstable angina pectoris. Mag. Lek. Rodz.12 (2004) (http://www.medicus.com.pl/lr/lr_arch_2004-12.html)
  • 108.Schnabel R., Rupprecht H.J., Lackner K.J., Lubos E., Bickel C., Meyer J., Münzel T., Cambien F., Tiret L., Blankenberg S. AtheroGene Investigators. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur. Heart J. 2005;26:241–249. doi: 10.1093/eurheartj/ehi036. [DOI] [PubMed] [Google Scholar]
  • 109.Kowalski J., Banach M., Barylski M., Grycewicz J., Irzmanski R., Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J. Cardiovasc. Pharmacol. 2006;48:143–147. doi: 10.1097/01.fjc.0000246150.52382.07. [DOI] [PubMed] [Google Scholar]
  • 110.Heusch P., Skyschally A., Leineweber K., Haude M., Erbel R., Heusch G. The interaction of coronary microembolization and ischemic preconditioning: A third window of cardioprotection through TNF-alpha. Arch. Med. Sci. 2007;3:83–92. [Google Scholar]
  • 111.Piechota M., Irzmański R., Banach M., Kowalski J., Pawlicki L. Impedance cardiography in haemodynamic monitoring of septic patients: a prospective study. Arch. Med. Sci. 2007;3:145–151. [Google Scholar]
  • 112.Schnabel R., Lubos E., Rupprecht H.J., Espinola-Klein C., Bickel C., Lackner K.J., Cambien F., Tiret L., Munzel T., Blankenberg S. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina. results from the AtheroGene Study. J. Am. Coll. Cardiol. 2006;47:552–558. doi: 10.1016/j.jacc.2005.09.039. [DOI] [PubMed] [Google Scholar]
  • 113.Omland T., Persson A., Ng L., O’Brien R., Karlsson T., Herlitz J., Hartford M., Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913–2918. doi: 10.1161/01.cir.0000041661.63285.ae. [DOI] [PubMed] [Google Scholar]
  • 114.Schaller B.J. . The role of endothelin in stroke: Experimental data and underlying pathophysiology. Arch. Med. Sci. 2006;2:146–158. [Google Scholar]
  • 115.Pidgeon G.B., Richards A.M., Nichols M.G. Differing metabolism and bioactivity of atrial and brain natriuretic peptide in essential hypertension. Hypertension. 1996;27:906–913. doi: 10.1161/01.hyp.27.4.906. [DOI] [PubMed] [Google Scholar]
  • 116.Gryglewski R.J. Interactions between endothelial mediators. Pharmacol. Toxicol. 1995;77:1–9. doi: 10.1111/j.1600-0773.1995.tb01906.x. [DOI] [PubMed] [Google Scholar]
  • 117.Ferro, C.J. and Webb, D.J. Endothelial dysfunction and hypertension. Drugs53 (Suppl. 1) 30–41. [DOI] [PubMed]
  • 118.Castillo J.R., Zagler A., Carrillo-Jimenez R., Hennekens C.H. Brain natriuretic peptide: a potential marker for mortality in septic shock. Int. J. Infect. Dis. 2004;8:271–274. doi: 10.1016/j.ijid.2003.12.007. [DOI] [PubMed] [Google Scholar]
  • 119.Charpentier J., Luyt C.E., Fulla Y., Vinsonneau C., Cariou A., Grabar S., Dhainaut J.F., Mira J.P., Chiche J.D. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit. Care Med. 2004;32:660–665. doi: 10.1097/01.ccm.0000114827.93410.d8. [DOI] [PubMed] [Google Scholar]
  • 120.Witthaut R. Science review: natriuretic peptides in critical illness. Crit. Care. 2004;8:342–349. doi: 10.1186/cc2890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Chua G., Kang-Hoe L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit. Care. 2004;8:248–250. doi: 10.1186/cc2889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Kato N., Sugiyama T., Morita H., Nabika T., Kurihara H., Yamori Y., Yazaki Y. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin. Sci. (London) 2000;98:251–258. [PubMed] [Google Scholar]
  • 123.Rubattu S., Giliberti R., Ganten U., Volpe M. A differential brain atrial natriuretic peptide expression co-segregates with occurrence of early stroke in the stroke prone phenotype of spontaneously hypertensive rat. J. Hypertens. 1999;17:1849–1852. doi: 10.1097/00004872-199917121-00011. [DOI] [PubMed] [Google Scholar]
  • 124.Gruchala M., Ciecwierz D., Wasag B., Targonski R., Dubaniewicz W., Nowak A., Sobiczewski W., Ochman K., Romanowski P., Limon J., Rynkiewicz A. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am. Heart J. 2003;145:125–131. doi: 10.1067/mhj.2003.52. [DOI] [PubMed] [Google Scholar]
  • 125.Nakayama T., Soma M., Saito S., Honye J., Sato M., Aoi N., Kosuge K., Haketa A., Kanmatsuse K., Kokubun S. Missense mutation of exon 3 in the type A human natriuretic peptide receptor gene is associated with myocardial infarction. Med. Sci. Monit. 2003;9:R505–CR510. [PubMed] [Google Scholar]
  • 126.Tiret L., Mallet C., Poirier O., Nicaud V., Millaire A., Bouhour J.B., Roizes G., Desnos M., Dorent R., Schwartz K., Cambien F., Komajda M. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J. Am. Coll. Cardiol. 2000;35:29–35. doi: 10.1016/s0735-1097(99)00522-7. [DOI] [PubMed] [Google Scholar]
  • 127.Ono K., Mannami T., Baba S., Yasui N., Ogihara T., Iwai N. A single-nucleotide polymorphism in C-type natriuretic peptide gene may be associated with hypertension. Hypertens. Res. 2002;25:727–730. doi: 10.1291/hypres.25.727. [DOI] [PubMed] [Google Scholar]
  • 128.Irzmański R., Piechota M., Barylski M., Banach M., Gławęda B., Kowalski J., Cierniewski C., Kośmider M., Pawlicki L. Dynamics of changes of the BNP concentration in patients with stable angina pectoris qualified for PTCA. Dependence on the selected morphological and haemodynamic parameters. Arch. Med. Sci. 2006;2:15–19. [Google Scholar]
  • 129.Topol E.J. Nesiritide — not verified. N. Engl. J. Med. 2005;353:113–116. doi: 10.1056/NEJMp058139. [DOI] [PubMed] [Google Scholar]
  • 130.Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491. doi: 10.1161/01.CIR.0000159340.93220.E4. [DOI] [PubMed] [Google Scholar]
  • 131.Sackner-Bernstein J.D., Kowalski M., Fox M., Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905. doi: 10.1001/jama.293.15.1900. [DOI] [PubMed] [Google Scholar]
  • 132.Meyer M., Pfarr E., Schirmer G., Uberbacher H.J., Schope K., Bohm E., Fluge T., Mentz P., Scigalla P., Forssmann W.G. Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren. Fail. 1999;21:85–100. doi: 10.3109/08860229909066972. [DOI] [PubMed] [Google Scholar]

Articles from Cellular & Molecular Biology Letters are provided here courtesy of BMC

RESOURCES